STAT News

STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class

The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.

Por STAT News

1 minuto de lectura
Compartir
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas